Such alterations have been noted in individuals with type 2 diabetes, obesity, and metabolic syndrome, though the precise mechanisms remain an active area of research
For years, there were few treatment options for patients
In clinical trials, tirzepatide reduced sleep apnea events by as much as two-thirds or about 66% over the course of 52 weeks in patients with obstructive sleep apnea
Plans are more likely to cover GLP-1s when theyre prescribed for type 2 diabetes than when theyre used for weight loss
And so, GLP-1 therapies improve weight, blood sugar and lipid profiles, and some have demonstrated cardiovascular event reduction in high-risk populations, which makes them particularly relevant for patients with RA who also have diabetes or obesity-related cardiovascular risk
If hair loss begins before starting semaglutide, persists beyond 6 months after weight loss stops, or causes bald patches, consult a dermatologist to evaluate thyroid function, iron levels, and other medical causes